Which mood stabilizer has a notable risk for Stevens-Johnson syndrome (SJS) in individuals of Asian descent?

Carbamazepine is associated with a significant risk of Stevens-Johnson syndrome (SJS), particularly in individuals of Asian descent. This increased risk is linked to the presence of the HLA-B*1502 allele, which is more prevalent in certain Asian populations. When these individuals are treated with carbamazepine, they are at a higher risk of developing severe skin reactions, including SJS or toxic epidermal necrolysis.

Due to this genetic predisposition, screening for the HLA-B*1502 allele is recommended before initiating treatment with carbamazepine in these populations, underscoring the importance of understanding pharmacogenetics in prescribing practices. The awareness of this risk factors into clinical decision-making, ensuring safer treatment plans for patients of Asian descent who may require mood stabilization.

Other mood stabilizers listed, such as valproic acid, lithium, and lamotrigine, do not carry the same level of risk for SJS associated with genetic factors in the Asian population, making carbamazepine the correct focus in this context.